FLT3 and acute myeloid leukemia: specifically evaluated the role of midostaurin maintenance after allogenic HCT in patients with FLT3-ITD positive AML, transplanted in first CR in a phase 2, randomized, open-label trial (RADIUS) that compared standard of care (SOC) with or without midostaurin.